tailieunhanh - báo cáo hóa học: " Boosting with intranasal dendrimeric Aβ1–15 but not Aβ1–15 peptide leads to an effective immune response following a single injection of Aβ1–40/42 in APP-tg mice"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Boosting with intranasal dendrimeric Aβ1–15 but not Aβ1–15 peptide leads to an effective immune response following a single injection of Aβ1–40/42 in APP-tg mice | Journal of Neuroinflammation BioMed Central Research Open Access Boosting with intranasal dendrimeric Ap 1-15 but not Ap 1-15 peptide leads to an effective immune response following a single injection of Ap 1-40 42 in APP-tg mice Timothy J Seabrook Liying Jiang Katelyn Thomas and Cynthia A Lemere Address Center for Neurologic Diseases Brigham and Women s Hospital Harvard Medical School Boston MA 02115 USA Email Timothy J Seabrook - tseabrook@ Liying Jiang - ljiang@ Katelyn Thomas - kethomas314@ Cynthia A Lemere - clemere@ Corresponding author Published 05 June 2006 Received 14 April 2006 Journal of Neuroinflammation 2006 3 14 doi 1742-2094-3-14 Accepted 05 June 2006 This article is available from http content 3 1 14 2006 Seabrook et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Immunotherapy for Alzheimer s disease AD is emerging as a potential treatment. However a clinical trial AN1792 was halted after adverse effects occurred in a small subset of subjects which may have been caused by a T cell-mediated immunological response. In general aging limits the humoral immune response therefore immunogens and vaccination regimes are required that induce a strong antibody response with less potential for an adverse immune response. Method In the current study we immunized both wildtype and J20 APP-tg mice with a priming injection of Ap 1-40 42 followed by multiple intranasal boosts with the novel immunogen dAp1-15 16 copies of Ap 1-15 on a lysine tree Ap 1-15 peptide or Ap 1-40 42 full length peptide. Results J20 APP-tg mice primed with Ap 1-40 42 subcutaneously and subsequently boosted intranasally with